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Despite recent insights into melanoma genetics,
systematic surveys for driver mutations are chal-
lenged by an abundance of passenger mutations
caused by carcinogenic UV light exposure.We devel-
oped a permutation-based framework to address
this challenge, employing mutation data from in-
tronic sequences to control for passenger mutational
load on a per gene basis. Analysis of large-scale
melanoma exome data by this approach discovered
six novel melanoma genes (PPP6C, RAC1, SNX31,
TACC1, STK19, and ARID2), three of which—RAC1,
PPP6C, and STK19—harbored recurrent and poten-
tially targetable mutations. Integration with chromo-
somal copy number data contextualized the land-
scape of driver mutations, providing oncogenic
insights in BRAF- and NRAS-driven melanoma aswell as those without known NRAS/BRAFmutations.
The landscape also clarified a mutational basis for
RB and p53 pathway deregulation in thismalignancy.
Finally, the spectrum of driver mutations provided
unequivocal genomic evidence for a direct muta-
genic role of UV light in melanoma pathogenesis.INTRODUCTION
In recent years, much has been learned about the molecular
basis of melanoma genesis, progression, and response to
therapy. BRAF V600 mutations (present in 50% of melanomas)
predict clinical efficacy of RAF inhibitors such as vemurafenib;
activating KIT aberrations may predict response to tyrosine
kinase inhibitors such as imatinib, nilotinib, or dasatinib, and
some NRAS mutant tumors may exhibit sensitivity to MEK inhi-
bition (reviewed in Flaherty et al., 2012). Other melanoma gene
mutations that offer therapeutic insights include CDNK2ACell 150, 251–263, July 20, 2012 ª2012 Elsevier Inc. 251
deletions, MITF amplification/alteration resulting in dysregula-
tion of ‘‘druggable’’ antiapoptotic proteins, and PTEN disruption
leading to PI3 kinase/AKT activation (reviewed in Chin et al.,
2006). The continuing discovery of recurrently mutated mela-
noma genes (Berger et al., 2012; Nikolaev et al., 2012; Stark
et al., 2012; Wei et al., 2011) and the lack of identified driver
mutations in the subtype without NRAS or BRAF mutation
suggest that genetic understanding of this malignancy remains
incomplete.
Although the potential of comprehensive genome sequencing
for melanoma gene discovery is recognized, there is also
increasing appreciation for the confounding impact of highmuta-
tional load due to UV mutagenesis. In particular, cutaneous
melanomas exhibit markedly elevated base mutation rates
compared to nearly all other solid tumors (Berger et al., 2012;
Pleasance et al., 2010), which is almost entirely attributable to
increased abundance of the cytidine to thymidine (C > T) transi-
tions characteristic of a UV-light-induced mutational signature.
Highly elevated somaticmutation rates that vary across genomic
loci may limit the ability of statistical approaches that assume
uniformity of the basal mutation rate to distinguish genes
harboring ‘‘driver’’ mutations (i.e., mutations that confer or at
some point conferred a fitness advantage to the tumor cell)
from those with ‘‘passenger’’ mutations (i.e., mutations that
never conferred a fitness advantage). Although methods to
account for this mutation rate heterogeneity are an active area
of research (Chapman et al., 2011; Greenman et al., 2006; Lohr
et al., 2012), rigorous approaches to address this challenge in
melanoma have been lacking.
A related question pertains to the tumorigenic effects of
UV-induced DNA damage at the nucleotide level. Epidemiolog-
ical and experimental data have established a causal role for
intense UV exposure during development (e.g., blistering
sunburns early in life) in melanoma genesis (reviewed in Garib-
yan and Fisher, 2010). Several model systems have also linked
UV-dependent tumorigenic effects to modulation of signaling
pathways (e.g., enhanced gamma interferon secretion [Zaidi
et al., 2011] and activation of c-Jun N-terminal kinase (JNK)
signaling pathway [De´rijard et al., 1994]), thus supporting a
nonmutagenic role in melanoma. Conversely, evidence for
a direct UV mutagenic effect in melanoma pathogenesis has
been more equivocal. For example, the recurrent base muta-
tions that produce oncogenic NRAS and BRAF mutations are
not C > T transitions indicative of UV mutagenesis. Definitive
resolution of this question requires demonstration of driver
mutations that are directly attributable to UV-induced damage
in melanoma.
To analyze whole-exome sequencing data from 121 mela-
noma tumor/normal pairs, we have employed a statistical
approach that infers positive selection at each gene locus based
on exon/intron mutational distributions, as well as the predicted
functional impact of each mutation. This approach enabled both
discovery of several new cancer genes with functionally conse-
quential (and plausibly actionable) mutations and identification
of numerous driver mutations directly attributable to UV muta-
genesis. In the aggregate, these results offer a comprehensive
view of the landscape of driver coding mutations in human
melanoma.252 Cell 150, 251–263, July 20, 2012 ª2012 Elsevier Inc.RESULTS
Identification of Melanoma Coding Mutations
by Whole-Exome Sequencing
Solution-phase hybrid capture and whole-exome sequencing
were performed on paired tumor and normal genomic DNA ob-
tained from 135 patients with melanoma (Tables S1 and S2 avail-
able online). 103-fold mean target coverage was achieved, with
87% of bases covered at least 14-fold in the tumor and 8-fold in
the normal—the threshold which offers 80% power to detect
mutations with an allelic fraction of 0.3 (Carter et al., 2012). A
set of 121 tumor/normal pairs (15 primary tumors, 30 metastatic
samples, and 76 short-term cultures derived from metastatic
tumor tissue [Table S1]) were qualified for analysis. Altogether,
this sample collection comprised 95 melanomas of cutaneous,
5 of acral, 2 of mucosal, 1 of uveal, and 18 of unknown primary
origin. Somatic copy-number aberration profiles identified ex-
pected melanoma alterations (Curtin et al., 2005; Lin et al.,
2008), including gains ofMITF, TERT, and CCND1 and deletions
ofCDKN2A and PTEN, among others (Figure S1A and Table S3).
Across all samples, 86,813 codingmutations were detected at
a 2:1 ratio of nonsynonymous to synonymous events, which is
consistent with a high passenger mutation load (Table S4). The
median sample mutation rate was 14.4 coding mutations per
megabase (lower-upper quartile range: 8.0–24.9). As expected,
this rate was higher than that reported for any other tumor
type, including lung cancer (Lee et al., 2010; Pasqualucci et al.,
2011; Cancer Genome Atlas Research Network, 2011), and
a signature of UV mutagenesis predominated (median YC > YT
mutations: 82.2%; lower-upper quartile range: 73.4%–86.5%).
Accordingly, 13,905 genes harbored a nonsilent mutation in at
least one tumor, 9,782 genes were thus mutated in two or
more tumors, 515 genes were mutated in >10% of tumors, and
78 genesweremutated in >20%of tumors (Figure S1B). In genes
mutated in >10% and >20% of samples, 85.5% and 85.2%
of nonsilent coding mutations resulted from YC > YT transitions,
respectively, suggesting that many high-frequency melanoma
gene mutations may derive from UV-associated passenger
events.
We next sought to identify genes showing statistical evidence
for positive selection for nonsilent mutations, which is a chal-
lenging task in the context of melanoma’s high and heteroge-
neous basal mutation rate. To illustrate the problem introduced
by regional heterogeneity in basal mutation rates, we defined
significantly mutated genes by using a standard analytical
approach that assumes a uniform basal mutation rate across
the exome (controlling for trinucleotide context), as published
previously (Ding et al., 2008; Getz et al., 2007; Kan et al., 2010;
Stransky et al., 2011; Cancer Genome Atlas Research Network,
2011). This analysis produced a long list of genes (n = 544) with
nonsilent mutation frequencies exceeding the exomic average,
thus considered ‘‘significantly’’ mutated (Figure S1C). Many
of these genes showed high silent mutation rates (correlation
of significance rank with silent mutation rate: R = 0.29,
p < 2.2 3 1016, Pearson’s; Figure S1D), suggesting locally
elevated basal mutation rates. Furthermore, numerous genes
were found to have minimal expression levels in melanoma
based on cross-cohort analysis of published RNA sequencing
(RNA-seq) data (correlation of significance rank with expression
level: R = 0.08 and p = 4.43 1016) (Berger et al., 2010), which
is consistent with published studies showing that genes with
lower expression levels tend to harbor increased somatic muta-
tion rates (Chapman et al., 2011; Pleasance et al., 2010). We also
observed an anticorrelation between gene expression andmuta-
tion rate in our data (R = 0.10 and p = 4.4 3 1016). Together,
these results highlighted the challenge of detecting positive
selection in the setting of variable basal mutation rates. Such
loci may accumulate frequent somatic mutations unrelated to
positive selection but were nonetheless deemed significant by
statistical approaches that assume uniform basalmutation rates.
Conversely, genes present in loci with low basal mutation rates
may accumulate few mutations. Here, evidence of positive
selection will only become apparent after accounting for this
reduced mutation rate. The high mutational burden linked to
UV exposure further exacerbates this problem in melanoma by
making heterogeneity in locus-specific mutation rates even
more pronounced.
Systematic Inference of Positive Selection at Putative
Melanoma Gene Loci
To more accurately ascertain positive selection in melanoma
genomes, we leveraged sequence data from flanking intronic
regions and other untranslated (UTR) DNA segments that are
captured alongside exonic targets during hybrid selection to
define the local base mutation rate. We reasoned that any DNA
sequence situated immediately adjacent to an exon is likely sub-
jected to similar mutagenic and repair processes as the exonic
sequence. Indeed, gene-specific intronic and exonic mutation
rates correlated in our data set across several orders of magni-
tude (R = 0.35 and p < 2.23 1016; Figure S1E). However, unlike
nonsilent mutations in their exonic counterparts, mutations in
intronic andUTR sequences aremore likely to exist under neutral
selective pressure. Thus, mutation data obtained from these
flanking regions should offer a means by which locus-specific
mutation rates might be inferred.
A gene that contains a high frequency of nonsilent exonic
mutations and a low frequency of synonymous or intronic/UTR
mutations exhibits presumptive evidence of positive selection
during tumor evolution. Such a mutational pattern may signify
the presence of bona fide driver mutations in melanoma. On
the other hand, a gene with a high frequency of both nonsilent
exonic mutations and synonymous, intronic, and/or UTR muta-
tions is less likely to contain mutations that experienced positive
selection during tumorigenesis (Figure 1A). Based on these prin-
ciples, a null model of the distribution of all mutations across the
gene (exon, intron, and UTR) may be generated by random
permutation of the locations of all observed mutations (Fig-
ure 1B). This null model is computed per sample, as the locus
basal mutation rate may vary across samples. A permutation
test may then be performed to assess the statistical significance
of any set-wide observation in the gene compared to the null
model generated from all individual sample null models.
Employing this framework, we assessed the statistical signifi-
cance of the set-wide ‘‘functional mutation burden’’: the number
of samples harboring a nonsilent mutation of predicted func-
tional consequence (Adzhubei et al., 2010). Eleven genes werefound to harbor a statistically significant functional mutation
burden (q % 0.2; Benjamini and Hochberg, 1995) (Figures 1C
and S1F and Table S5). These included six well-known cancer
genes (BRAF, NRAS, PTEN, TP53, p16INK4a [transcript of the
CDKN2A gene locus], and MAP2K1) and five new candidates
(PPP6C, RAC1, SNX31, TACC1, and STK19). Manual review
and mass spectrometric genotyping of observed mutations at
these loci confirmed high nonsynonymous:synonymous muta-
tion ratios and low rates of silentmutations (Figure 1C and Tables
S5 and S6). Contrary to the output from the initial significance
analysis (described above), an overall bias toward lowly ex-
pressed genes was no longer evident (R = 0.04 and p = 6.2
3 106). As a control, we performed an analogous assessment of
the ‘‘synonymous mutation burden,’’ and no genes were identi-
fied as statistically significant by this analysis (Figure 1C and
Table S7). Thus, the incorporation of exonic and nonexonic
mutational data identified multiple loci that showed evidence of
positive selection and hence may contain genes that harbor
driver mutations.
Novel Melanoma Genes Are Linked to Known
Cancer-Relevant Pathways
The five novel candidate genes harboring putative somatic driver
mutations (PPP6C, RAC1, SNX31, TACC1, and STK19) had not
previously been recognized as significantly mutated in mela-
noma. PPP6C encodes for the catalytic subunit of the heterotri-
meric PP6 protein phosphatase complex (Stefansson et al.,
2008). Reports have implicated PPP6C as a tumor suppressor
due to its role in regulation of cell cycle and mitosis. PP6 nega-
tively regulates levels of the melanoma oncogeneCCND1 during
G1 phase of the cell cycle (Stefansson and Brautigan, 2007) and
is the major T-loop phosphatase for the mitotic kinase, Aurora A
(AurA), which is amplified in a number of human cancers (Lens
et al., 2010; Zeng et al., 2010). In the discovery set of 121
tumor/normal pairs, 11 melanomas (9%) harbored nonsynony-
mousPPP6Cmutations, 10 of whichwere predicted to be homo-
zygous events based on high mutant allele frequencies. 60% of
these PPP6C mutations clustered within a 12 amino acid region
flanking an arginine at codon 264 (four R264C mutations, two
S270L mutations, and one P259S mutation; Figure 2A). When
mapped onto the structure of the PP2A catalytic subunit
(60% sequence homology to PPP6C; Figures 2A and S2A),
the PPP6C mutations localized to highly conserved regions. In
particular, R264 participates in multiple salt bridge interactions
at the interface between the catalytic and regulatory subunits
(Cho and Xu, 2007). The PPP6C R264C mutation was found at
a frequency of 3% in an extension set of 63 melanoma samples
(Table S8). Homozygous hot spot (defined as same amino acid
change in >3% of samples in the discovery set of 121) mutations
in R264 and nearby residues may result in altered interactions
between the PPP6C catalytic subunit and its regulatory partners.
The clustered mutation pattern and relative paucity of nonsense
mutations or frameshift indels are characteristic of gain-of-func-
tion mutations, suggesting that dysregulation of this protein
phosphatase’s function may contribute to melanoma biology.
Mutations in STK19 (a predicted kinase with unknown func-
tion) exhibited a hot spot pattern in melanoma. Six nonsynony-
mous STK19 mutations were detected in five tumors (4%) inCell 150, 251–263, July 20, 2012 ª2012 Elsevier Inc. 253
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Figure 1. Detection of Positive Selection for Nonsilent Mutations
(A) Gene A locus displaying a greater rate of nonsilent mutation compared to silent and intronic mutation rate (left) indicative of positive selection for nonsilent
mutations and gene B locus displaying approximately equivalent rates of nonsilent mutation and silent/intronic mutation (right) indicative of a nonsilent mutation
rate that matches the basal locus mutation rate.
(B) Schema of permutation-based framework for identifying genes harboring positively selected nonsilent mutations.
(C) Q-Q plot of functional mutation burden test (l = 1.02) and synonymous mutation burden test across all genes with at least one mutation in the set of 121
sequenced samples. Dashed line indicates q% 0.2 for the functional mutation burden test. Gray-shaded area represents 95% confidence interval for expected
p values.
Please see also Figure S1.the discovery set (Figure 2B), four of which were located at D89
(D89N) with an immediately adjacent additional mutation (P90L).
D89N mutation showed a consistent frequency (5%) in a mela-
noma extension set of 59 tumors (Table S8). The pattern and
significance of its somatic hot spot point mutations are strong
genomic evidence in support of STK19 as a cancer gene.
In contrast, TACC1 and SNX31 exhibited a distributed pattern
of mutational events. SNX31 encodes the poorly characterized
protein sorting nexin 31. Mutations tended to occur within the
protein and lipid interaction band4.1/ezrin/radixin/moesin
(FERM)-like domain of SNX31 (Figure 2C), with one mutation in
the domain occurring in two separate melanoma cases and
over 60% of nonsilent mutations occurring in a 48 residue
window in this 440 residue protein. SNX31 has been reported
to bind active guanosine triphosphate (GTP)-loaded H-Ras, but
not inactive guanosine diphosphate (GDP)-loaded H-Ras, likely
through its FERM-like domain (Ghai et al., 2011), which suggests
a potential role for SNX31 as a Ras effector protein.
TACC1, encoding transforming acidic coiled-coil protein 1,
has been reported to stimulate the Ras and PI3K pathways
and to promote transformation in mice upon overexpression254 Cell 150, 251–263, July 20, 2012 ª2012 Elsevier Inc.(Cully et al., 2005). TACC1 is mutated in eight melanomas (7%)
in the discovery set, with mutations occurring predominately
near the C terminus of the protein, in or near the conserved
TACC domain (Figure 2D). TACC1 is known to interact with
AurA (Conte et al., 2003; Delaval et al., 2004), which is notable
in the context of PPP6C’s function as an AurA phosphatase
(Zeng et al., 2010).
Finally, 5% of discovery set melanomas harbored nonsilent
mutations in RAC1, a RAS-related member of the Rho subfamily
of GTPases. RAC1 functions as a molecular switch, cycling
between active GTP-bound and inactive GDP-bound states
through large conformation changes near the nucleotide-binding
site, localized to the switch I and II regions. Its best-character-
ized function is regulation of cytoskeleton rearrangement, and
thus it plays important roles in cellular adhesion, migration, and
invasion (Jaffe and Hall, 2005). Overexpression has been
reported in a number of malignancies (Karlsson et al., 2009).
RAC1mutations in our melanomas exhibited a hot spot pattern,
with all six mutations effecting the same nucleotide change (Fig-
ure 3A). This c.85C > T transition, resulting in a P29S amino acid
change, is the most frequent hot spot mutation after those in
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Figure 2. Significantly Mutated Genes PPP6C, STK19, SNX31, and TACC1
(A–D) Schematic diagram of domains and mutations of PPP6C, STK19, SNX31 and TACC1. Structure of the PPP6C homologous protein PP2A (PDB: 2IAE) with
mapped PPP6C somatic mutations (all mutated residues are conserved between the two proteins except for PPP6C S270, which maps to PP2AC A274)
(A, bottom). Salt bridge interactions represented by dashed lines in zoom image. PPP motifs, protein phosphatase; Ub-like, ubiquitin-related fold; PTB-like,
phosphotyrosine binding (PTB); PX, Phox homology; FERM-like domain, Band 4.1 (F), Ezrin (E), Radixin (R), and Moesin (M); SPAZ, Ser-Pro Azu-1 motif; TACC,
transforming acidic coiled coil.
Please see also Figure S2.BRAF and NRAS (Table S9). Including verification data from two
independent extension sets (n = 59 and n = 175), the prevalence
of RAC1 P29S hot spot mutation in melanoma was validated to
be 3.9% (14/355 patients; Tables S8 and S10). In addition, muta-
tions in homologous residues in RAC2 (P29L) and RHOT1 (P30L)
were also found (Figure 3B), highlighting the importance of the
P29 residue as a possible codon targeted by hot spot mutations
in Rho family GTPases. We also observed a known RAS family-
activating mutation (G12D) (reviewed in Malumbres and Barba-
cid, 2003) in a gene encoding for another Rho family GTPasemember, CDC42 (Figure 3B). Together, these mutational data
implicate the Rho family members as melanoma oncogenes.
RAC1 P29S Mutation Is a Gain-of-Function Oncogenic
Event
To explore possible consequences of the RAC1 P29S mutation,
we conducted homology modeling based on crystal structures
of the 97% amino-acid-sequence-identical RAC3 in GDP-bound
and GTP/PAK1-bound conformations (Figures S3A and S3B). In
the GDP-bound state, P29 is found in a hydrophobic pocket inCell 150, 251–263, July 20, 2012 ª2012 Elsevier Inc. 255
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RAC1, RAC2, RHOT1, and CDC42.switch I, and S29 is predicted to be energetically less favorable
due to its lack of shape complementarity, reduced hydropho-
bicity, and unfavorable proximity of the serine hydroxyl oxygen
to adjacent hydrophobic residues (Figure 4A, bottom left and
right). In the GTP-bound state, the packing of the switch 1 loop
is less compact (Figure 4B, top left and right). The energetic
advantage of having the wild-type P29 rather than the mutant
S29 is therefore lost. Conversely, S29 is predicted to engage in
hydrogen bonds with the polar side and main chains of E31,
which would stabilize the GTP-bound form (Figure 4B, bottom
left and right). Furthermore, the P29S mutant is predicted to
gain more entropy upon transitioning from the GDP- to the
GTP-bound form than wild-type because, in the GDP-bound
state, switch 1 is tethered to the protein core, whereas in the
GTP-bound state, switch 1 flexibility is restricted by P29 (Fig-
ure S3C). These observations suggest that P29S mutation likely
destabilizes RAC1’s inactive GDP-bound state and favors its
active GTP-bound state.
Because active, GTP-loaded RAC1 is known to interact with
the p21-binding domain (PBD) of p21-activated protein kinase
1 (PAK1) to regulate downstream events relevant for tumorigen-
esis, PAK1 PBD pull-down assays can be employed to measure
GTP-bound RAC1. In HEK293FT cells, PAK1 PBD pull-down
revealed a significantly higher fraction of RAC1(P29S) in the
GTP-loaded active statewhen compared towild-type (Figure 4C,
compare lanes 2 and 3). As expected, a constitutively active
RAC1(Q61L) mutant was found in a robust GTP-loaded fraction
(Figure 4C, compare lane 2 to 4 and 5). In the presence of exog-
enous GDP, RAC1(P29S) demonstrated an attenuated shift to
the inactive, GDP-bound form, which was in accordance with
the structural prediction (Figure 4D, compare lanes 1 and 2 to
4 and 5). Importantly, the increase in GTP-loaded RAC1(P29S)
was also evident in immortalized human melanocytes stably256 Cell 150, 251–263, July 20, 2012 ª2012 Elsevier Inc.expressing oncogenic NRAS or BRAF
(Figures 4E and 4F). Together, the bio-
chemical and structural results support
the conclusion that theRAC1 P29Smuta-
tion is activating, rendering RAC1 prefer-
entially in an active, GTP-bound state.
Predicted Loss-of-Function
Melanoma Gene Mutations
Mutations in putative tumor suppressor
genes that result in protein truncation
may carry a higher likelihood of conferring
a fitness advantage to the tumor cell
compared to the effect of missensemuta-tions in the same genes. As the permutation-based framework
described above modeled basal mutation rates without regard
to functional consequence of mutations, we next employed it
to detect genes with a higher ‘‘loss-of-function (LoF) mutation
burden’’ than was expected by chance. LoF mutations were
defined as nonsense, splice-site, and frameshift events. Both
p16INK4a and ARID2 showed statistically significant LoF burden
(q% 0.2; Table S11), with p16INK4a LoFmutations in 14 discovery
samples (12%) and ARID2 LoF mutations in 9 samples (7%).
All nonsensemutations inARID2, which encodeda component
of the SWI/SNF chromatin-remodeling complex, were predicted
to yield truncated variants lacking the C2H2 Zn-finger motifs
required for DNA binding (5% of samples) (Figure 5A), which is
reminiscent of the inactivating ARID2 mutations found in hepa-
titis-C-virus-associated hepatocellular carcinomas (Li et al.,
2011). Although ARID2 has not been previously identified as
significantly mutated in melanoma, singleton mutations—all
nonsense events—have been reported in three studies (Nikolaev
et al., 2012; Stark et al., 2012;Wei et al., 2011). A targeted search
for LoF mutations in other components of the SWI/SNF complex
identified three nonsense mutations in ARID1B (a gene that also
had a significant LoF burden, though it did not pass correction for
multiple hypothesis testing in our discovery set), three in
ARID1A, and one in SMARCA4 (Figure 5B). Thus, 13%
(16/121) of the discovery samples harbored a LoF mutation in
a component of the SWI/SNF complex, suggesting a role for dys-
regulation of chromatin remodeling in melanomagenesis.
A Landscape of Driver Mutations in Melanoma
The identification of known and novel drivers in this study
provided a global view of melanoma gene mutations. By cross-
referencing all observed mutations to recurrently mutated base
pairs (nR 20) reported in the COSMIC database (Forbes et al.,
A B
C D
E F
Anti-Vinculin
Anti-GFP
Anti-GFP
Anti-Vinculin
Anti-GFP
Anti-GFP
Anti-Vinculin
Anti-GFP
Anti-GFP
Anti-Vinculin
Anti-GFP
Anti-GFP
M
O
C
K
W
T
P2
9S
T1
7N
Q
61
L
PAK1 PBD PULL DOWN
PAK1 PBD PULL DOWN
PAK1 PBD PULL DOWN PAK1 PBD PULL DOWN
Total RAC1
Total RAC1
Total RAC1
W
T
P2
9S
M
O
C
K
W
T
P2
9S
M
O
C
K
W
T
P2
9S
N
T
G
D
P
G
TP
γS
N
T
G
D
P
G
TP
γS
INPUTINPUT
INPUT
I21
C18
I33
P34
I21
T17
P29P29
P34
P29S
I21
P34
I21
T17
P29S
C18
I33
P34
P29S
I21 T17
E31
P29S
I21 T17
E31
P29
I21
T17
E31
C18
1      2      3     1      2      3     
1     2     3     4     5     6     
INPUT
P29
I21
T17
E31
C18
Active RAC1
(GTP loaded)
Active RAC1
(GTP loaded)
Active RAC1
(GTP loaded)
Active RAC1
(GTP loaded)1     2     3     4     5     
RAC1 
WT
RAC1
P29S
IB:
IB:
IB:
:GFP-RAC1
:GFP-RAC1
:GFP-RAC1
:GFP-RAC1
IB:
Total RAC1
pMEL-NRAS pMEL-BRAF
Figure 4. RAC1 P29S Is Activating
(A) Homology model (based on PDB entry 2G0N) zoom images onto P29 (top) and P29S (bottom) in the GDP-bound form are shown.
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(E and F) Following transfection of immortalized melanocytes (pMEL) stably expressing mutant forms of NRAS or BRAF (F).
Please see also Figure S3.
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Figure 5. Loss-of-Function Mutations in
ARID2
(A) Schematic diagram of domains and mutations
in ARID2.
(B) Loss-of-function (nonsense, frameshift indel,
and splice-site) mutations in ARID2, ARID1B,
ARID1A, and SMARCA4 across sequenced
samples.2011), we augmented this viewwith rare driver events whose low
frequency precluded statistical identification. This identified
driver mutations in CTNNB1, PIK3CA, p14ARF (alternative tran-
script of the CDKN2A gene locus), EZH2, IDH1, GNA11, KIT,
HRAS, and WT1 (Figure 6A and Table S12). To provide a fuller
context to the landscape, focal amplifications or deletions of
signature melanoma genes, such as amplifications in CCND1,
KIT, CDK4, and TERT and deletions in CDKN2A and PTEN,
were delineated in the same set of samples.
Integrating these mutational and copy number data, we map-
ped the spectrum of driver genes in Figure 6A. As expected, 83%
(100/121) of melanoma samples harbored either a hot spot or
a COSMIC-recurrent mutation (referred to hereafter as ‘‘highly
recurrent’’ mutations) inNRAS (n = 27) orBRAF (n = 73) in amutu-
ally exclusive fashion (p = 33 1014, Fisher’s exact test). The two
cases with co-occurring BRAF and NRAS mutations harbored
either a non-V600 BRAF mutation, together with an oncogenic
NRAS mutation, or an NRAS mutation not known to be onco-
genic, together with an activating BRAF mutation. Nearly 44%
(32/73) of melanomas with highly recurrent mutations in BRAF
harbored a PTEN mutation or focal deletion; conversely, PTEN
was altered in only 4% (1/27) of melanomas with highly recurrent
mutations in NRAS (p = 4.93 105) (Figure S4A). Significance of
these mutational patterns was confirmed by a pairwise search
across all genes in Figure 6A (q% 0.2; Table S13).
The melanoma discovery set included 21 tumors without
highly recurrent mutations in either BRAF or NRAS (‘‘BRAF/
NRAS wild-type’’ samples) (Figure 6B). A search for genes
mutated in at least 25% of these samples and ranked among
the top 50 genes by functional mutation burden identified NF1.
A significant enrichment of NF1 mutations was observed in this
subset; putative loss-of-function NF1 mutations occurred in 5
of 21 of these tumors (25%) compared to 2 of the remaining
100 samples (2%) (p = 5.8 3 103) (Figure 6B). Given the role
of NF1 as a negative regulator of RAS signaling (Vigil et al.,
2010), these results suggest that NF1 inactivation may confer258 Cell 150, 251–263, July 20, 2012 ª2012 Elsevier Inc.aberrant mitogen-activated protein
kinase (MAPK) pathway activation in
these BRAF/NRAS wild-type samples. In
addition, an activating HRAS G13I muta-
tion, an activating CRAF E478K mutation
(Emuss et al., 2005), and two MAP2K1
mutations were observed in BRAF/
NRAS wild-type samples that were also
NF1 wild-type (Figure 6B). Of the 13 re-
maining BRAF/NRAS wild-type samples,
1 harbored an activatingKIT V559Amuta-
tion, 6 (1 of which was acral and 1 ofwhich was mucosal) showed focal amplification of KIT,
CCND1, and/or CDK4, and 1 (a uveal melanoma) possessed
an activating GNA11 Q209L mutation. Altogether, known mela-
noma driver events spanned 81% (17/21) of cases that lacked
highly recurrent NRAS or BRAFmutations (Figure 6B), providing
a unified view of driver mutations in this subtype of melanomas.
CDKN2A is a well-known melanoma tumor suppressor gene
that encodes for two tumor suppressor proteins through alterna-
tive splicing: (1) p16INK4a, a cyclin-dependent kinase inhibitor
that activates retinoblastoma (RB) through negative regulation
of CDK4, and (2) p14ARF, which activates p53 through inhibition
of its major negative regulator, MDM2 (Chin et al., 2006). The
p16INK4a transcript was mutated in greater than 20% of our
discovery set, with 14 out of 25 mutations being putative LoF
events. Coupled with one splice-site and two nonsense muta-
tions in RB1, as well as three R24 activating mutations in
CDK4, we estimated that the cell cycle checkpoint was deregu-
lated directly through somatic mutations of its core components
in at least 24% (29/121) of samples.Most of themelanoma cases
harboring p53 mutation (19% in the discovery set) were without
concurrent mutation in p14ARF or p16INK4a (Figure S4B). Taken
together, these data support the consensus view that genetic
pressure to mutate p53 directly in melanoma is reduced due to
frequent deletion of the CDKN2A locus, and these data also
show that p53 mutation is prevalent in a subset of melanoma
without p14ARF mutation.
Finally, LoF mutations in members of the SWI/SNF complex,
together with COSMIC-recurrent mutations in EZH2 and IDH1,
were found in 17% (20/121) of melanomas, providing genomic
evidence that chromatin-modifying proteins and epigenetic
regulators contribute to melanoma genesis or progression.
The Role of UV Mutagenesis in the Advent of Melanoma
Driver Gene Mutations
Next, we systematically addressed the direct effect of misrepair
of UV-induced DNA damage as a cause of melanoma driver
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Please see also Figure S4.
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Figure 7. Signature of UV Mutagenesis across Driver Mutations
(A and B) Total number (A) and percentage (B) of driver mutations caused
by UVB single nucleotide variant (SNV) (C > T), UVA SNV (G > T), UVB in half
of dinucleotide variant (DNV) (NC > NT; CN > TN), and UVA in half of DNV
(NG > NT; GN > TN) are indicated. Dotted line indicates exome-wide sample
median percentage UVB SNV (C > T).mutations, namely C > T (by UVB) or G > T (by UVA). Specifically,
we assessed the distribution of mutations attributable to UV-
induced DNA damage among the driver mutations. Out of the
262 driver mutations in 21 genes defined by our analysis, 46%
were caused by C > T (37%) or G > T (9%) mutations character-
istic of UVB/UVA-induced mutations. This percentage increased
to 67% (103/150) when driver mutations in BRAF or NRAS were
excluded.
TP53 possessed the greatest number of total putative UV-
induced mutations among mutated melanoma genes identified
in this study (Figure 7A), challenging the dogma that often cites
its wild-type status as characteristic of human melanomas
(Chin et al., 2006; Flaherty et al., 2012). Presumed UV-induced
LoF mutations in known melanoma tumor suppressors (PTEN,
p14ARF, and p16INK4a) were also evident. Newly discovered
significantly mutated genes ARID2, PPP6C, SNX31, and
TACC1 each had a high fraction of mutations attributed to
C > T transitions, suggesting a possible role in UVB-induced
melanomagenesis.
The majority of known activating mutations in the MAPK
pathway, which include BRAF (c.1799T > A encoding V600E)
(n = 63), NRAS (c.182A > T, Q61L and c.182A > G, Q61R)
(n = 16), KIT (c.1676T > C, V559A) (n = 1), and GNA11
(c.626A > T, Q209L) (n = 1), do not appear attributable to direct
UV-induced damage (Figure 7A). There are possible exceptions
in mutations in BRAF, in which all dinucleotide mutations
include a C > T transition, including V600E (c.1799–1800TG >
AA) (n = 1), V600K (c.1798–1799GT > AA) (n = 7), V600R
(c.1798–1799GT > AG) (n = 1), and L597S (c.1789–1790CT >260 Cell 150, 251–263, July 20, 2012 ª2012 Elsevier Inc.TC) (n = 1), that could be attributed to UVB-induced mutagen-
esis. There are also mutations in RAS, including NRAS Q61K
(c.181C > A and c.180–181AC > CA) (n = 9), Q61R (c.181–
182CA > AG) (n = 1), G12D (c.35G > A) (n = 1), and HRAS
G13I (c.37–38GG > AT) (n = 1), which may result from UVA-
and UVB-induced damage.
Four genes, RAC1, STK19, FBXW7, and IDH1, all possessed
a relative percentage of C > T mutations that was above the
exome-wide per-sample median (83%). Notably, the hot spot
mutations PPP6C R264C, STK19 D89N, and RAC1 P29S are
each mediated solely by presumptive UVB damage (Figure 7B).
Given evidence that P29S renders RAC1 preferentially in GTP-
bound form, leading to downstream activation of PAK signaling
(Figure 4), our data revealed the first example of a hot-spot-
activating mutation in a melanoma gene attributable to direct
UVB-mediated damage, providing definitive evidence for UV
mutagenesis in melanoma pathogenesis.
DISCUSSION
We described here a permutation-based framework (available
for download at http://www.broadinstitute.org/software/invex/)
that leverages intron and UTR sequences in a gene locus to
control for gene-specific basal mutation rates, which is a
conceptual advance that represents a natural but important
evolution of prior works. Pioneering studies have led to
increasing appreciation of the confounding effects of variable
regional basal mutation rates, motivating refinements such as
gene-specific basal mutation rate calculations based on synon-
ymous mutations, binning genes based on expression levels to
correct for correlation between expression and mutation rate,
and within-gene permutation tests to assess positional clus-
tering and evolutionary conservation of mutated residues
(Chapman et al., 2011; Ding et al., 2008; Greenman et al.,
2006; Kan et al., 2010; Lohr et al., 2012). We expect that future
research will account for within-gene variation in the basal muta-
tion rate and, with enough data, per-base basal mutation rates
can eventually be inferred. Local rate-altering events will also
need to be considered; for example, somatic rearrangements
have recently been reported to elevate the local mutation rate
(Nik-Zainal et al., 2012). Our results should motivate refinement
of the standard exon-capture bait set to expressly target
a portion of intron/UTR segments for use in basal mutation rate
modeling. With whole-genome sequence data, which fully
covers introns and UTRs, our approach can be more robust
and can offer increased statistical power.
Although we have assessed the significance of a gene’s func-
tional mutation burden by using PolyPhen-2 (Adzhubei et al.,
2010) in this study (as well as LoF mutation burden), other muta-
tion scoring algorithms (Cooper and Shendure, 2011) may too
prove useful. Increased cohort sizes (which will emerge in the
fullness of time through The Cancer Genome Atlas [TCGA] and
other large-scale efforts) will give sufficient power to evaluate
the significance of the more naive ‘‘nonsilent mutation burden,’’
which does not depend on functional prediction scores. More
broadly, this methodology of modeling locus-specific basal
mutation rates in combination with optional functional weighting
can improve the identification of driver mutations in nonexonic
genomic regions predicted to experience positive selection,
such as conserved regulatory domains.
Although mutation prevalence of the novel melanoma genes
identified herein is relatively low, their importance extends
beyond melanoma, as underscored by cross-tumor relevance
and protein family recurrence. For example, RAC1 P29S muta-
tion has been reported in a head and neck tumor (Stransky
et al., 2011) and in a breast tumor (Forbes et al., 2011); further-
more, homologous P29 mutations in other Rho family members
were observed in melanoma (Figure 3). The appearance of
singleton known activating mutations in our cohort, such as
those seen in HRAS, GNA11, and KIT, predicts that larger
sequencing studies will uncover additional melanoma genes, re-
affirming the importance of systematic resequencing in statisti-
cally powered sets of human cancers.
Finally, although sun exposure has been shown to be a leading
risk factor for melanoma (Garibyan and Fisher, 2010), it has been
perplexing that the most prevalent UVB-radiation-induced
genetic change—the transition of a cytosine to a thymidine,
accounting for >70% of nucleotide substitutions—has not
been shown to be the molecular basis for known oncogenic
mutations in melanoma, including BRAF V600E and NRAS
Q61L/R. The identification of statistically significant hot spot
mutations inRAC1,STK19, and PPP6C resulting fromC> T tran-
sitions offers missing genomic evidence linking UVB mutagen-
esis mechanistically to this malignancy.EXPERIMENTAL PROCEDURES
Clinical Samples
All melanoma samples analyzed in this study were collected and se-
quenced under Institution-Review-Board-approved protocols (MIT/COUHES
110700457). The DNeasy Tissue Kit or the QIAmp DNA Mini Kit (QIAGEN, Va-
lencia, CA) was used to extract genomic DNA from tissues. The Puregene DNA
Purification Kit (Gentra Systems, Minneapolis, MN) was used to extract
genomic DNA from short-term cultures. All DNA samples were subjected to
quality assessment.
DNA Library Preparation, Whole-Genome Sequencing, and
Assembly
Exome capture and library construction were performed as in Gnirke et al.
(2009) and were adapted for production-scale exome capture. Libraries
were sequenced on Illumina HiSeq 2000 machines, generating 2 3 76 bp
paired-end reads. Sequencing data obtained from the Illumina pipeline were
processed by the Picard pipeline (http://picard.sourceforge.net/).
High-Density SNP Arrays
DNA samples were hybridized to Affymetrix SNP Array 6.0 genome-wide
human SNP microarrays (Affymetrix, Santa Clara, CA), and chromosomal
copy number segments were determined as described previously (Cancer
Genome Atlas Research Network, 2008). A gene was identified as focally
amplified/deleted if a segment above absolute value 0.6 of length%5 Mb in-
tersected the gene. Significantly recurrent amplifications and deletions were
identified by using GISTIC (Beroukhim et al., 2007).
Exome Quality Assessment
Samples with nonaberrant copy number profiles and normal samples with
aberrant copy number profiles were removed from analysis. Each lane from
a tumor/normal pair was cross-checked to have the same SNP fingerprint
as each other lane from that pair; nonmatching lanes were removed from anal-
ysis. Cross-contamination was estimated by using ContEst (Cibulskis et al.,2011) (Table S1B). Samples with greater than 10% contamination were
excluded from further consideration.
Identification of Somatic Substitutions and Indels
Somatic base-pair substitutions were identified by using MuTect (https://
confluence.broadinstitute.org/display/CGATools/MuTect), and somatic small
indels were identified by using Indelocator (https://confluence.broadinstitute.
org/display/CGATools/Indelocator), as in previous reports (Stransky et al.,
2011). Identified somatic mutations were annotated for effect of the mutation
on the protein product by using Oncotator, a comprehensive parsing script for
mutation annotation (https://confluence.broadinstitute.org/display/CGATools/
Oncotator). Each of the above algorithms or scripts was executed within the
Broad Firehose infrastructure (https://confluence.broadinstitute.org/display/
CGATools/Firehose).
Mutational Significance Assuming Uniform Background Mutation
Rate
An initial attempt at mutational significance analysis assuming a uniform
background mutation rate was performed by using the per-sample version
of MutSig described in the supplement of Getz et al. (2007).
Statistical Determination of Positive Selection for Nonsilent
Mutations
For each gene with at least one observed somatic mutation, the observed
mutation burden score was calculated (see below for three such score defini-
tions). Mutations were permuted randomly across the gene’s covered base
pairs, respecting trinucleotide context, and the mutation burden score of
the randomized instance was calculated. Up to 108 random instances were
generated and scored. The fraction of mutation burden scores for random
instances that was equal to or greater than the observed burden defined
the p value.
(1) Functional mutation burden: mutations were weighted with their Poly-
Phen-2 p value (Adzhubei et al., 2010). Frameshift indels, nonsense and
splice-site mutations, and mutations at a nucleotide mutated R5 times in
COSMIC (Forbes et al., 2011) were given a weight of 1. The mutation with
the largest weight was identified in each sample, and the sum of these largest
weights was defined as the functional mutation burden. (2) Synonymousmuta-
tion burden: the number of samples with R1 synonymous mutation. (3) LoF
mutation burden: the number of samples withR1 nonsense mutation, frame-
shift indel, or splice-site mutation. (To increase statistical power, we assessed
excess LoF mutation burden above 2.)
The source code for this method, termed InVEx (for ‘‘Introns versus Exons’’),
is available at http://www.broadinstitute.org/software/invex/.
Mutation Validation and Extension
Mass spectrometric genotyping (Sequenom) on melanoma samples and
accompanying normal tissue was performed as previously described (Stran-
sky et al., 2011; Thomas et al., 2007). MassEXTEND primers were designed
by using MassARRAY Assay Design Software from Sequenom, Inc. to
generate allele-specific products.
Homology Modeling and Structural Analysis
The structural analysis compared wild-type and P29S mutants of both
GDP-bound apo-RAC1 and GTP-bound RAC1 in complex with the PAK1
Cdc42/Rac interactive binding (CRIB) domain. Crystallographic models for
RAC1 exist for the GTP-bound state (1MH1) and for a particular Zn-bound
trimeric version of GDP-RAC1 (2P2L). However, a GTP and PAK1 CRIB-bound
crystal structure exists for RAC3 (2QME, 97% identical to RAC1 for all residues
included in the crystal structure; Figure S3). GDP-RAC3 has also been crystal-
lized (2G0N). RAC1 and RAC3 structures are highly similar and superimpose
with a root-mean-square distance (rmsd) of 1.1 A˚ and 0.9 A˚ for GDP- and
GTP-bound forms, respectively. To nonetheless avoid any influence of local
structural distortions due to the Zn-bound trimeric conformation of the GDP-
RAC1 structure, a homology model of RAC1 was built based on GDP-RAC3,
and this model was compared with a homology model of GTP-RAC1 bound
to PAK1 CRIB. Homology models were built by using SWISS-MODEL (Arnold
et al., 2006).Cell 150, 251–263, July 20, 2012 ª2012 Elsevier Inc. 261
Cell Culture
Human primary melanocytes (pMEL/hTERT/CDK4(R24C)/p53DD) expressing
either BRAF(V600E) (pMEL-BRAF) or NRAS(G12D) (pMEL-NRAS) have been
previously described (Garraway et al., 2005; Scott et al., 2011). HEK293FT
cells were obtained from Life Technologies (Grand Island, NY). All cells were
maintained in Dulbecco’s modified Eagle’s medium (Cellgro, Manassas, VA)
in 10% heat-inactivated fetal bovine serum (FBS) at 37C in a humidified 5%
CO2 atmosphere.
Plasmids
pcDNA3-EGFP-RAC1 (wild-type, T17N, and Q61L) were obtained from Addg-
ene (plasmids 13719, 13720, and 13721) courtesy of Klaus Hahn (Kraynov
et al., 2000). pcDNA3-EGFP-RAC1(P29S) was generated by using Quik-
Change Lightning Site-Directed Mutagenesis (Stratagene, Santa Clara, CA)
according to the manufacturer’s instruction.
RAC1 Activation Assay
Equal amounts of pcDNA3-EGFP-RAC1 plasmids were transiently trans-
fected with Lipofectamine 2000 reagent (Invitrogen), and 48 hr posttrans-
fection RAC1 activation assay was performed according to themanufacturer’s
protocol (Cell Biolabs, Inc.). Briefly, cells growing in monolayers were lysed
in 10 cm tissue culture plates, cell lysates were cleared by centrifuga-
tion, and protein concentrations were determined by DC Protein Assay
(BioRad). Lysates were diluted to equal concentrations, and RAC1 pull-
down assays were performed with equal amounts of protein by using GST
fusion proteins containing the PBD of PAK1 coupled to glutathione agarose
beads for 1 hr. Pull-downs in the presence of exogenous GDP/GTPgS were
performed according to manufacturer’s instructions, followed by Western
analysis.
ACCESSION NUMBERS
The dbGaP accession number for the exome sequence data reported in this
paper is phs000452.v1.p1.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, four
figures, and thirteen tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2012.06.024.
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